RecruitingPhase 1NCT07784959

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

Sponsor

Nuvectis Pharma, Inc.

Enrollment

54 participants

Start Date

Aug 17, 2026

Study Type

INTERVENTIONAL

Conditions

NSCLC ALK-positive Non-small Cell Lung Cancer ALK+ Non-Small-Cell Lung Carcinoma ALK Positive

Summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Lorlatinib and a drug called NXP900 for people with alk positive, alk+ non-small-cell lung carcinoma, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.